Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.

Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2019 Feb;33(2):554-558. doi: 10.1038/s41375-018-0274-y. Epub 2018 Oct 12. No abstract available.

PMID:
30315233
2.

Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, Meshinchi S, Stirewalt DL.

Biopreserv Biobank. 2018 Feb;16(1):42-52. doi: 10.1089/bio.2017.0079. Epub 2017 Nov 27. Erratum in: Biopreserv Biobank. 2018 Apr;16(2):168.

3.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

4.

NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.

VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A.

J Natl Compr Canc Netw. 2016 Nov;14(11):1357-1370.

PMID:
27799507
5.

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2016 Oct;30(10):2080-2083. doi: 10.1038/leu.2016.120. Epub 2016 May 2. No abstract available.

6.

Immobilized Metal Affinity Chromatography Coupled to Multiple Reaction Monitoring Enables Reproducible Quantification of Phospho-signaling.

Kennedy JJ, Yan P, Zhao L, Ivey RG, Voytovich UJ, Moore HD, Lin C, Pogosova-Agadjanyan EL, Stirewalt DL, Reding KW, Whiteaker JR, Paulovich AG.

Mol Cell Proteomics. 2016 Feb;15(2):726-39. doi: 10.1074/mcp.O115.054940. Epub 2015 Nov 30.

7.

Transcriptome Profiling of Pediatric Core Binding Factor AML.

Hsu CH, Nguyen C, Yan C, Ries RE, Chen QR, Hu Y, Ostronoff F, Stirewalt DL, Komatsoulis G, Levy S, Meerzaman D, Meshinchi S.

PLoS One. 2015 Sep 23;10(9):e0138782. doi: 10.1371/journal.pone.0138782. eCollection 2015.

8.

Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.

Qu X, Davison J, Du L, Storer B, Stirewalt DL, Heimfeld S, Estey E, Appelbaum FR, Fang M.

Epigenetics. 2015;10(6):526-35. doi: 10.1080/15592294.2015.1048060.

9.

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

J Clin Oncol. 2015 Apr 1;33(10):1157-64. doi: 10.1200/JCO.2014.58.0571. Epub 2015 Feb 23. Erratum in: J Clin Oncol. 2015 May 20;33(15):1715.

10.

Sample processing obscures cancer-specific alterations in leukemic transcriptomes.

Dvinge H, Ries RE, Ilagan JO, Stirewalt DL, Meshinchi S, Bradley RK.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16802-7. doi: 10.1073/pnas.1413374111. Epub 2014 Nov 10.

11.

Quantitative and stoichiometric analysis of the microRNA content of exosomes.

Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyan EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS, Tewari M.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14888-93. doi: 10.1073/pnas.1408301111. Epub 2014 Sep 29.

12.

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML.

Stirewalt DL, Pogosova-Agadjanyan EL, Tsuchiya K, Joaquin J, Meshinchi S.

Blood Cancer J. 2014 May 2;4:e208. doi: 10.1038/bcj.2014.27.

13.

The human salivary proteome is radiation responsive.

Moore HD, Ivey RG, Voytovich UJ, Lin C, Stirewalt DL, Pogosova-Agadjanyan EL, Paulovich AG.

Radiat Res. 2014 May;181(5):521-30. doi: 10.1667/RR13586.1. Epub 2014 Apr 10.

14.
15.

Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .

Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Weir AB 3rd, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2014 Jan;12(1):82-126.

PMID:
24453295
16.

MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors.

Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, Oehler VG.

PLoS One. 2013 Sep 24;8(9):e75815. doi: 10.1371/journal.pone.0075815. eCollection 2013.

17.

The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.

Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

PLoS One. 2013 Aug 14;8(8):e70812. doi: 10.1371/journal.pone.0070812. eCollection 2013.

18.

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.

Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH.

Br J Haematol. 2013 Oct;163(1):130-2. doi: 10.1111/bjh.12450. Epub 2013 Jul 6. No abstract available.

19.

Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets.

Foss EJ, Radulovic D, Stirewalt DL, Radich J, Sala-Torra O, Pogosova-Agadjanyan EL, Hengel SM, Loeb KR, Deeg HJ, Meshinchi S, Goodlett DR, Bedalov A.

J Proteome Res. 2012 Oct 5;11(10):5005-10. doi: 10.1021/pr300567r. Epub 2012 Sep 11.

20.

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP, Sandmaier BM, Sorror M, Stirewalt DL, Wilson WA, Storb R, Appelbaum FR, Gooley T.

Blood. 2012 Aug 16;120(7):1398-408. doi: 10.1182/blood-2012-04-423046. Epub 2012 Jul 5.

21.

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Leukemia. 2013 Jan;27(1):238-41. doi: 10.1038/leu.2012.168. Epub 2012 Jun 22. No abstract available.

22.

Comparison of Two Methods for Detecting Alternative Splice Variants Using GeneChip(®) Exon Arrays.

Fan W, Stirewalt DL, Radich JP, Zhao L.

Int J Biomed Sci. 2011 Sep;7(3):172-80.

23.

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.

Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26.

24.

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.

Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH.

Br J Haematol. 2011 Oct;155(2):182-9. doi: 10.1111/j.1365-2141.2011.08831.x. Epub 2011 Aug 18.

25.

Blood-based detection of radiation exposure in humans based on novel phospho-Smc1 ELISA.

Ivey RG, Moore HD, Voytovich UJ, Thienes CP, Lorentzen TD, Pogosova-Agadjanyan EL, Frayo S, Izaguirre VK, Lundberg SJ, Hedin L, Badiozamani KR, Hoofnagle AN, Stirewalt DL, Wang P, Georges GE, Gopal AK, Paulovich AG.

Radiat Res. 2011 Mar;175(3):266-81. doi: 10.1667/RR2402.1. Epub 2010 Dec 20.

26.

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.

Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8. doi: 10.1073/pnas.1019055108. Epub 2011 Mar 7.

27.

Identification of radiation-induced expression changes in nonimmortalized human T cells.

Pogosova-Agadjanyan EL, Fan W, Georges GE, Schwartz JL, Kepler CM, Lee H, Suchanek AL, Cronk MR, Brumbaugh A, Engel JH, Yukawa M, Zhao LP, Heimfeld S, Stirewalt DL.

Radiat Res. 2011 Feb;175(2):172-84. Epub 2010 Nov 17.

28.

Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.

Newell LF, Gooley T, Hansen JA, Stirewalt DL, Petersdorf EW, Deeg HJ.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1700-6. doi: 10.1016/j.bbmt.2010.06.003. Epub 2010 Jun 9.

29.

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S.

Blood. 2010 Aug 5;116(5):702-10. doi: 10.1182/blood-2010-02-268953. Epub 2010 Apr 22.

30.

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Leukemia. 2010 May;24(5):909-13. doi: 10.1038/leu.2010.56. Epub 2010 Apr 8.

31.

Gene expression changes in normal haematopoietic cells.

Lionberger JM, Stirewalt DL.

Best Pract Res Clin Haematol. 2009 Jun;22(2):249-69. doi: 10.1016/j.beha.2009.05.005. Review.

PMID:
19698932
32.

The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E, Ladne P, Stirewalt DL, Abkowitz JL, Radich JP.

Blood. 2009 Oct 8;114(15):3299-308. doi: 10.1182/blood-2008-07-170282. Epub 2009 Jul 22.

33.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S.

Blood. 2009 Jun 25;113(26):6558-66. doi: 10.1182/blood-2008-10-184747. Epub 2009 Mar 20.

34.

Receptor tyrosine kinase alterations in AML - biology and therapy.

Stirewalt DL, Meshinchi S.

Cancer Treat Res. 2010;145:85-108. doi: 10.1007/978-0-387-69259-3_6. Review.

PMID:
20306247
35.

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.

Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR.

Blood. 2009 Jan 22;113(4):866-74. doi: 10.1182/blood-2007-12-124818. Epub 2008 Oct 16.

36.

Circulating microRNAs as stable blood-based markers for cancer detection.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.

37.

Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells.

Stirewalt DL, Choi YE, Sharpless NE, Pogosova-Agadjanyan EL, Cronk MR, Yukawa M, Larson EB, Wood BL, Appelbaum FR, Radich JP, Heimfeld S.

Leukemia. 2009 Feb;23(2):391-3. doi: 10.1038/leu.2008.176. Epub 2008 Jul 3. No abstract available. Erratum in: Leukemia. 2009 Feb;23(2):430.

38.

Structural and numerical variation of FLT3/ITD in pediatric AML.

Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP.

Blood. 2008 May 15;111(10):4930-3. doi: 10.1182/blood-2008-01-117770. Epub 2008 Feb 27.

39.

Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.

Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2865-70. doi: 10.1073/pnas.0712391105. Epub 2008 Feb 19.

40.

Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?

Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, Radich JP, Deeg HJ.

Br J Haematol. 2008 Feb;140(4):444-53. Epub 2007 Dec 19.

PMID:
18162123
41.

Identification of genes with abnormal expression changes in acute myeloid leukemia.

Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP.

Genes Chromosomes Cancer. 2008 Jan;47(1):8-20.

PMID:
17910043
42.

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2007 Mar;13(3):355-65.

43.

Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.

Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP.

Blood. 2007 Apr 1;109(7):3080-3.

44.

Use of gene expression microarrays for the study of acute leukemia.

Bellido M, Stirewalt DL, Zhao LP, Radich JP.

Expert Rev Mol Diagn. 2006 Sep;6(5):733-47. Review.

PMID:
17009907
45.

Clinical implications of FLT3 mutations in pediatric AML.

Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP.

Blood. 2006 Dec 1;108(12):3654-61. Epub 2006 Aug 15.

46.

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.

Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA.

Leukemia. 2006 Jul;20(7):1295-7. Epub 2006 Apr 20. No abstract available.

PMID:
16628187
47.

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL.

Blood. 2006 Jul 15;108(2):685-96. Epub 2006 Apr 4.

48.

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP.

Blood. 2006 May 1;107(9):3724-6. Epub 2005 Dec 20.

49.

A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication.

Kussick SJ, Stirewalt DL, Yi HS, Sheets KM, Pogosova-Agadjanyan E, Braswell S, Norwood TH, Radich JP, Wood BL.

Leukemia. 2004 Oct;18(10):1591-8.

PMID:
15343344
50.

Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.

Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP.

Blood. 2004 Nov 15;104(10):3058-63. Epub 2004 Jun 24.

Supplemental Content

Loading ...
Support Center